NVO:NYSE
Novo Nordisk A/S
$37.54
arrow_upward
+0.59%(+0.22) 1D
$37.35
arrow_downward
-0.51% (-0.19)todayPre-market
Closed: Oct 5, 4:00:04 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVO...
Open
$36.94
High
$37.61
Low
$36.86
Mkt. cap
127.59B
Avg. vol.
12.90M
Volume
175.54K
Dividend
4.79%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
9.52
52-wk high
$64.16
52-wk low
$35.12
EPS
$3.94
Beta
0.75
Shares outstanding
3.39B
No. of employees
67K
Open
$36.94
High
$37.61
Low
$36.86
Mkt. cap
127.59B
Avg. vol.
12.90M
Volume
175.54K
Dividend
4.79%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
9.52
52-wk high
$64.16
52-wk low
$35.12
EPS
$3.94
Beta
0.75
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
AD HOC NEWS
·
4 hours ago
Novo Nordisk stock ahead of the Xetra open at EUR 33.43 on October 5, 2026
AD HOC NEWS
·
7 hours ago
Novo Nordisk Keeps Buying Back Its Own Stock as Pipeline Deals and FDA Delays Shape the Story
AD HOC NEWS
·
15 hours ago
Novo-Nordisk stock gains a fresh DKK 15 billion buyback signal
Zacks
·
19 hours ago
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7K
FoundedDec 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com